We have located links that may give you full text access.
[Clinical-hemodynamic and anti-ischemic effects ivabradine and nebivolol ischemic heart disease with left ventricular dysfunction].
Georgian Medical News 2010 October
The aim of this study was to examine the effectiveness of Ivabradine (available under the brandnames of Procoralan, Coralan, Corlentor, Coraxan, "Servier", France) and Nebivolol (Nebilet, "Berlin-Chemie", Germany) with combination of standard therapy in patients with coronary artery disease and left ventricular dysfunction. A total of 72 patients (mean age 57.3±4,5 years) have been observed during 6 months. Patients were divided into 3 groups (standard therapy; standard therapy and Nebilet; standard therapy and Coraxan). The results showed that Coraxan with combination therapy compared optimally reduced heart rate and ensure a proper anti-ischemic effect, expressed as reduced left ventricular dysfunction, improved the degree of congestive heart failure than the group Nebilet.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app